

AMENDMENTS**IN THE SPECIFICATION:**

Kindly amend the specification as shown in the attached sheets (pages 4-14).

IN THE CLAIMS:

Kindly amend the claims as follows:

Please amend claims 1 and 2, as shown in the attached sheets (pages 15-17).

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and remarks below.

Claims 1, 2, 7, 13, 14, 25-28, 30, 32 35, 50, 51, 53-55, 62, and 63 are pending in this application. Claims 51, 53-54, and 62-63 have been withdrawn from consideration.

Applicants would like to thank Examiner Robinson for taking the time to discuss the present application by phone. Applicants noted during the call that an Amendment was filed on December 19, 2008. Examiner Robinson believes that those amendments were not entered due to misannotation of that reply. Examiner Robinson suggested resubmitting the same amendments in the present reply. Accordingly, Applicants have resubmitted amendments made to the Specification and to the Claims.

Claims 1 and 2 have been amended. Support for the amended claim may be found, for example, on pages 19 and 20 of the specification. These claim amendments are made to clarify the subject matter therein. These amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Rejection Under 35 U.S.C. § 112, first paragraph

Examiner has maintained the rejection to claims 1, 2, 7, 13, 14, 25-28, 30, 32 35, 50 and 55 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

Applicants have amended the claims 1 and 2 to remove the language cited by Examiner, "in no more than 15 amino acid residues." As presently presented, claim 1 provides a Factor VII or Factor VIIa polypeptide variant having the modification L65Q.